Olokizumab - CISMeF

Preferred Label : Olokizumab;

NCIt definition : A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), with potential immunomodulating and anti-inflammatory activities. Upon administration, olokizumab targets, binds to and blocks the activity of IL-6, which may inhibit the binding of IL-6 to its receptor interleukin-6 receptor (IL-6R). This may inhibit the IL-6/IL-6R-mediated signal transduction pathway and the associated inflammatory response.;

UNII : PAI71R1D2W;

CAS number : 1007223-17-7;

Molecule name : CDP 6038; CDP-6038;

NCI Metathesaurus CUI : CL1406734;

Details

Origin ID

C172654;

UMLS CUI

C3885146;

Currated CISMeF NLP mapping
- olokizumab [MeSH concept]
- olokizumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- olokizumab [MeSH Supplementary Concept]
- olokizumab [MeSH concept]
- olokizumab [ATC Code]
Validated automatic mappings to BTNT
- olokizumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients